Landfar Bio medicine Co

Landfar Bio medicine Co AAQS

The The AAQS of Landfar Bio medicine Co (000504.SZ) as of Nov 4, 2026 is 4. In the previous year, The AAQS was 4.00 — a change of 0.00% (lower).

AAQS

4

YoY

0.00%

Last updated:

Landfar Bio medicine Co has a current AAQS of 4.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Landfar Bio medicine Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Landfar Bio medicine Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
4.00 CNY
Jan 1, 2019
4.00 CNY
Jan 1, 2020
4.00 CNY
Jan 1, 2021
4.00 CNY
Jan 1, 2022
4.00 CNY
Jan 1, 2023
4.00 CNY
Jan 1, 2024
4.00 CNY
Jan 1, 2025
4.00 CNY
The Landfar Bio medicine Co AAQS history
YEARAAQSYoY
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
40.00%
4—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Landfar Bio medicine Co Stock analysis

What does Landfar Bio medicine Co do? NanHua Bio-medicine Co., Ltd. generates revenue through the manufacture and sale of pharmaceutical products, stem cell storage and technical services, stem cell treatment research, medical instrument purchasing and sales, as well as energy management company (EMC) contract energy management, build-transfer (BT), product sales, and sewage treatment. The company serves domestic customers seeking pharmaceuticals, stem cell services, medical instruments, and environmental solutions. Its biomedical segment focuses on stem cell-related offerings, while the energy conservation and environmental protection segment handles EMC, BT, and sewage treatment services. The firm operates exclusively within the domestic market, targeting businesses and consumers needing healthcare and environmental services. The company's revenue streams include pharmaceutical manufacturing, stem cell storage, medical instrument sales, and environmental services like EMC and BT projects. Domestic clients, including healthcare providers and environmental management firms, purchase these services and products. NanHua Bio-medicine Co., Ltd. leverages its domestic market presence to provide integrated solutions in healthcare and environmental sectors, with no international operations or external partnerships mentioned in its business description. Landfar Bio medicine Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Landfar Bio medicine Co stock

The AAQS of Landfar Bio medicine Co is 4 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Landfar Bio medicine Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — Landfar Bio medicine Co

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — Landfar Bio medicine Co